Rockefeller University 
Welcome,         Profile    Billing    Logout  
 8 Products   1 Disease  8 Products   14 Trials   657 News 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead
TITAN, NCT03837756 / 2018-001165-16: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Completed
2a
47
Europe, US, RoW
Saline, Lefitolimod, MGN1703, 3BNC117 and 10-1074, RUhumab-001 and RUhumab-002
University of Aarhus, Aalborg University Hospital, Odense University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, The Peter Doherty Institute for Infection and Immunity, University of Utah, Oslo University Hospital
HIV-1-infection
07/22
05/23
2015-005238-23: The effect of anti-latency reversing therapy and broadly neutralizing antibodies on the HIV-1 reservoir in patients on antiretroviral therapy - a randomized trial (ROADMAP) Effekten af et latensreverterende lægemiddel og neutraliserende antistoffer på HIV-1 reservoiret blandt personer i antiretroviral behandling – et randomiseret studie (ROADMAP)

Ongoing
2
30
Europe
Romidepsin, 3BNC117, Infusion, Istodax
Rockefeller University, The Rockefeller University, amfAR, Bill and Melinda Gates Foundation, American foundation for AIDS research (amfAR), The Bill and Melinda Gates Foundation
HIV infection HIV infektion, HIV infection HIV infektion, Diseases [C] - Virus Diseases [C02]
 
 
eCLEAR, NCT03041012 / 2015-002234-53: Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Completed
2
60
Europe
Romidepsin, Istodax, 3BNC117, Broadly neutralizing antibody, Antiretrovirals, ART
Aarhus University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, Odense University Hospital, Aalborg University Hospital, Herning Hospital, Hammersmith Hospitals NHS Trust, St Mary's Hospital, London
Hiv
08/21
12/22
NCT04819347: Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Not yet recruiting
2
24
RoW
Albuvirtide, ABT, 3BNC117
Frontier Biotechnologies Inc.
HIV/AIDS
06/22
12/22
NCT04560569: Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Recruiting
2
20
US
Albuvirtide, ABT, 3BNC117 Antibody, 3BNC117
Frontier Biotechnologies Inc.
HIV/AIDS
11/22
12/22
NCT03719664: Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Recruiting
2
80
US
Albuvirtide, Fusion inhibitor, 3BNC117, Monoclonal antibody, Baseline ART, ART
Frontier Biotechnologies Inc.
HIV-1-infection
12/22
12/22
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22
C144-LS / BMS
NCT04518410: ACTIV-2: A Study for Outpatients With COVID-19

Hourglass Jul 2022 - Dec 2022 : Data from ACTIV-2 trial for COVID-19
Hourglass May 2022 - Dec 2022 : Data from ACTIV-2 trial for the treatment of COVID-19
Checkmark Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Jan 2022 - Jan 2022: Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Checkmark Data from ACTIV-2 trial in combination with BRII-198 for COVID-19
More
Completed
2/3
4044
Canada, US, RoW
bamlanivimab 7000mg, LY3819253, BRII-196+BRII-198, AZD7442 (IV), AZD8895 + AZD1061, AZD7442 (IM), SNG001, Camostat, FOY-305, camostat mesilate, camostat mesylate, BMS-986414 + BMS-986413, C135-LS + C144-LS, SAB-185 (3,840 Units/kg), Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, REGN10933 + REGN10987, REGN-COV2, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
National Institute of Allergy and Infectious Diseases (NIAID), Eli Lilly and Company, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Brii Biosciences Limited, AstraZeneca, Sagent Pharmaceuticals, Synairgen Research Ltd., Bristol-Myers Squibb, SAb Biotherapeutics, Inc.
Coronavirus, Covid19
04/22
06/23
10-1074-LS-J / IAVI, Rockefeller University
NCT04173819: Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

Completed
1/2
225
US, RoW
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
International AIDS Vaccine Initiative, Fred Hutchinson Cancer Center, Rockefeller University, Brigham and Women's Hospital
HIV-1-infection
09/23
09/23
PAUSE, NCT06031272: Pausing Antiretroviral Treatment Under Structured Evaluation

Recruiting
1
48
RoW
3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J, Placebo for 10-1074-LS-J
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
06/25
06/26
zinlirvimab (GS-2872) / Gilead
2019-002129-31: The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART

Not yet recruiting
2
72
Europe
3BNC117-LS, 10-1074-LS, 3BNC117-LS, 10-1074-LS, Solution for infusion
Imperial College London, Bill & Melinda Gates Foundation
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
RIO, NCT04319367 / 2019-002129-31: A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

Recruiting
2
72
Europe
Investigational Medicinal Product, 10-1074-LS and 3BNC117-LS
Imperial College London, Bill and Melinda Gates Foundation, University of Oxford, Rockefeller University
HIV/AIDS and Infections
07/27
07/27
ACACIA, NCT06205602: Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Recruiting
2
135
RoW
3BNC117-LS, 10-1074-LS, Placebo for 3BNC117-LS, Placebo for 10-1074-LS
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
02/29
02/29
NCT05729568: A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active, not recruiting
2
83
Canada, US, RoW
Teropavimab, GS-5423, Zinlirvimab, GS-2872, Lenacapavir Tablet, GS-6207, Lenacapavir Injection, Antiretroviral Therapy
Gilead Sciences
HIV Infections
07/24
12/29
RHIVIERA-02, NCT05300035: Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

Recruiting
2
69
Europe
Recombinant human monoclonal antibody (bNAbs), 10-1074-LS and 3BNC117-LS, Placebo, Saline solution
ANRS, Emerging Infectious Diseases, Rockefeller University, Institut Pasteur
HIV/AIDS and Infections
12/26
12/28
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
NCT04811040: Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Completed
1
32
US
Oral Lenacapavir, GS-6207, Subcutaneous Lenacapavir, Teropavimab, 3BNC117-LS, GS-5423, Zinlirvimab, 10-1074-LS, GS-2872
Gilead Sciences
HIV-1 Infection
06/22
10/23
NCT05245292: 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Active, not recruiting
1
28
US
3BNC117-LS, broadly neutralizing antibody, monoclonal antibody, 10-1074-LS, N803, IL-15 superagonist complex
Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID), Weill Medical College of Cornell University, University of Pennsylvania
Human Immunodeficiency Virus
12/25
12/25
NCT05612178: A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Recruiting
1
200
US
3BNC117-LS, 10-1074-LS, Sterile Saline
National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1
12/25
12/25
teropavimab (GS-5423) / Gilead
2021-003040-25: A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact on post-treatment HIV control.

Not yet recruiting
2
60
Europe
3BNC117-LS, 10-1074-L-S, 3BNC117-LS, 10-1074-L-S, Solution for infusion, CHLORURE DE SODIUM FRESENIUS 0,9 %
Inserm-ANRS, ANRS|Maladies infectieuses émergentes
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active, not recruiting
1
118
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26
2141-V11 / Memorial Sloan-Kettering Cancer Center, Rockefeller University
NCT06347705: A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Recruiting
2
99
US
2141-V11 Antibody
Memorial Sloan Kettering Cancer Center
Prostate Cancer
03/29
03/29
NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting
1/2
50
US
D2C7-IT, 2141-V11
Darell Bigner, Rockefeller University
Newly Diagnosed MGMT Unmethylated Glioblastoma
10/26
10/28
DKN-0993, NCT04059588: A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

Completed
1
16
US
2141 V-11
Rockefeller University
Cancer, Solid Tumor, Cancer of Skin
03/23
03/23
NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting
1
90
US
D2C7-IT, 2141-V11, anti-CD40
Darell Bigner, Rockefeller University
Glioma, Malignant
06/26
06/27
NCT05126472: Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Recruiting
1
55
US
anti-CD40 antibody 2141-V11
Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer Research Foundation, Rockefeller University
Non-muscle Invasive Bladder Cancer
11/26
11/26
NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in RGBM

Recruiting
1
46
US
D2C7-IT, 2141 V11
Darell Bigner, Rockefeller University
Recurrent Glioblastoma IDH Wildtype
01/29
01/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead
TITAN, NCT03837756 / 2018-001165-16: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Completed
2a
47
Europe, US, RoW
Saline, Lefitolimod, MGN1703, 3BNC117 and 10-1074, RUhumab-001 and RUhumab-002
University of Aarhus, Aalborg University Hospital, Odense University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, The Peter Doherty Institute for Infection and Immunity, University of Utah, Oslo University Hospital
HIV-1-infection
07/22
05/23
2015-005238-23: The effect of anti-latency reversing therapy and broadly neutralizing antibodies on the HIV-1 reservoir in patients on antiretroviral therapy - a randomized trial (ROADMAP) Effekten af et latensreverterende lægemiddel og neutraliserende antistoffer på HIV-1 reservoiret blandt personer i antiretroviral behandling – et randomiseret studie (ROADMAP)

Ongoing
2
30
Europe
Romidepsin, 3BNC117, Infusion, Istodax
Rockefeller University, The Rockefeller University, amfAR, Bill and Melinda Gates Foundation, American foundation for AIDS research (amfAR), The Bill and Melinda Gates Foundation
HIV infection HIV infektion, HIV infection HIV infektion, Diseases [C] - Virus Diseases [C02]
 
 
eCLEAR, NCT03041012 / 2015-002234-53: Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Completed
2
60
Europe
Romidepsin, Istodax, 3BNC117, Broadly neutralizing antibody, Antiretrovirals, ART
Aarhus University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, Odense University Hospital, Aalborg University Hospital, Herning Hospital, Hammersmith Hospitals NHS Trust, St Mary's Hospital, London
Hiv
08/21
12/22
NCT04819347: Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Not yet recruiting
2
24
RoW
Albuvirtide, ABT, 3BNC117
Frontier Biotechnologies Inc.
HIV/AIDS
06/22
12/22
NCT04560569: Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Recruiting
2
20
US
Albuvirtide, ABT, 3BNC117 Antibody, 3BNC117
Frontier Biotechnologies Inc.
HIV/AIDS
11/22
12/22
NCT03719664: Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Recruiting
2
80
US
Albuvirtide, Fusion inhibitor, 3BNC117, Monoclonal antibody, Baseline ART, ART
Frontier Biotechnologies Inc.
HIV-1-infection
12/22
12/22
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Active, not recruiting
1
15
US
Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies
Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS, HIV-1 Infection
12/21
10/22
C144-LS / BMS
NCT04518410: ACTIV-2: A Study for Outpatients With COVID-19

Hourglass Jul 2022 - Dec 2022 : Data from ACTIV-2 trial for COVID-19
Hourglass May 2022 - Dec 2022 : Data from ACTIV-2 trial for the treatment of COVID-19
Checkmark Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Jan 2022 - Jan 2022: Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Checkmark Data from ACTIV-2 trial in combination with BRII-198 for COVID-19
More
Completed
2/3
4044
Canada, US, RoW
bamlanivimab 7000mg, LY3819253, BRII-196+BRII-198, AZD7442 (IV), AZD8895 + AZD1061, AZD7442 (IM), SNG001, Camostat, FOY-305, camostat mesilate, camostat mesylate, BMS-986414 + BMS-986413, C135-LS + C144-LS, SAB-185 (3,840 Units/kg), Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, REGN10933 + REGN10987, REGN-COV2, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
National Institute of Allergy and Infectious Diseases (NIAID), Eli Lilly and Company, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Brii Biosciences Limited, AstraZeneca, Sagent Pharmaceuticals, Synairgen Research Ltd., Bristol-Myers Squibb, SAb Biotherapeutics, Inc.
Coronavirus, Covid19
04/22
06/23
10-1074-LS-J / IAVI, Rockefeller University
NCT04173819: Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

Completed
1/2
225
US, RoW
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
International AIDS Vaccine Initiative, Fred Hutchinson Cancer Center, Rockefeller University, Brigham and Women's Hospital
HIV-1-infection
09/23
09/23
PAUSE, NCT06031272: Pausing Antiretroviral Treatment Under Structured Evaluation

Recruiting
1
48
RoW
3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J, Placebo for 10-1074-LS-J
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
06/25
06/26
zinlirvimab (GS-2872) / Gilead
2019-002129-31: The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART

Not yet recruiting
2
72
Europe
3BNC117-LS, 10-1074-LS, 3BNC117-LS, 10-1074-LS, Solution for infusion
Imperial College London, Bill & Melinda Gates Foundation
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
RIO, NCT04319367 / 2019-002129-31: A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

Recruiting
2
72
Europe
Investigational Medicinal Product, 10-1074-LS and 3BNC117-LS
Imperial College London, Bill and Melinda Gates Foundation, University of Oxford, Rockefeller University
HIV/AIDS and Infections
07/27
07/27
ACACIA, NCT06205602: Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Recruiting
2
135
RoW
3BNC117-LS, 10-1074-LS, Placebo for 3BNC117-LS, Placebo for 10-1074-LS
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
02/29
02/29
NCT05729568: A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active, not recruiting
2
83
Canada, US, RoW
Teropavimab, GS-5423, Zinlirvimab, GS-2872, Lenacapavir Tablet, GS-6207, Lenacapavir Injection, Antiretroviral Therapy
Gilead Sciences
HIV Infections
07/24
12/29
RHIVIERA-02, NCT05300035: Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

Recruiting
2
69
Europe
Recombinant human monoclonal antibody (bNAbs), 10-1074-LS and 3BNC117-LS, Placebo, Saline solution
ANRS, Emerging Infectious Diseases, Rockefeller University, Institut Pasteur
HIV/AIDS and Infections
12/26
12/28
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
NCT04811040: Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Completed
1
32
US
Oral Lenacapavir, GS-6207, Subcutaneous Lenacapavir, Teropavimab, 3BNC117-LS, GS-5423, Zinlirvimab, 10-1074-LS, GS-2872
Gilead Sciences
HIV-1 Infection
06/22
10/23
NCT05245292: 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Active, not recruiting
1
28
US
3BNC117-LS, broadly neutralizing antibody, monoclonal antibody, 10-1074-LS, N803, IL-15 superagonist complex
Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID), Weill Medical College of Cornell University, University of Pennsylvania
Human Immunodeficiency Virus
12/25
12/25
NCT05612178: A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Recruiting
1
200
US
3BNC117-LS, 10-1074-LS, Sterile Saline
National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1
12/25
12/25
teropavimab (GS-5423) / Gilead
2021-003040-25: A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact on post-treatment HIV control.

Not yet recruiting
2
60
Europe
3BNC117-LS, 10-1074-L-S, 3BNC117-LS, 10-1074-L-S, Solution for infusion, CHLORURE DE SODIUM FRESENIUS 0,9 %
Inserm-ANRS, ANRS|Maladies infectieuses émergentes
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active, not recruiting
1
118
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26
2141-V11 / Memorial Sloan-Kettering Cancer Center, Rockefeller University
NCT06347705: A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Recruiting
2
99
US
2141-V11 Antibody
Memorial Sloan Kettering Cancer Center
Prostate Cancer
03/29
03/29
NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting
1/2
50
US
D2C7-IT, 2141-V11
Darell Bigner, Rockefeller University
Newly Diagnosed MGMT Unmethylated Glioblastoma
10/26
10/28
DKN-0993, NCT04059588: A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

Completed
1
16
US
2141 V-11
Rockefeller University
Cancer, Solid Tumor, Cancer of Skin
03/23
03/23
NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting
1
90
US
D2C7-IT, 2141-V11, anti-CD40
Darell Bigner, Rockefeller University
Glioma, Malignant
06/26
06/27
NCT05126472: Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Recruiting
1
55
US
anti-CD40 antibody 2141-V11
Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer Research Foundation, Rockefeller University
Non-muscle Invasive Bladder Cancer
11/26
11/26
NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in RGBM

Recruiting
1
46
US
D2C7-IT, 2141 V11
Darell Bigner, Rockefeller University
Recurrent Glioblastoma IDH Wildtype
01/29
01/30

Download Options